Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,347 | 11 | 98.2% |
| Food and Beverage | $24.53 | 2 | 1.8% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI PASTEUR INC. | $1,347 | 11 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $12.53 | 1 | $0 (2022) |
| PFIZER INC. | $12.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,347 | 11 | SANOFI PASTEUR INC. ($1,347) |
| 2022 | $24.53 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($12.53) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $66.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $381.74 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $311.71 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $160.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $159.02 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 09/07/2022 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $12.53 | General |
| 03/16/2022 | PFIZER INC. | PREVNAR 13 (Biological), TRUMENBA | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: VACCINES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | SANOFI PASTEUR INC. | $1,347 | 11 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 258 | 258 | $38,313 | $24,006 |
| 2022 | 1 | 77 | 77 | $5,775 | $3,144 |
| 2021 | 3 | 52 | 68 | $4,725 | $2,857 |
| 2020 | 1 | 15 | 15 | $1,066 | $184.35 |
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 91322 | Sarscov2 vac 50 mcg/0.5ml im | Office | 2023 | 129 | 129 | $28,380 | $18,447 | 65.0% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 129 | 129 | $9,933 | $5,559 | 56.0% |
| 0134A | Fee covid-19 vac 14 res | Office | 2022 | 77 | 77 | $5,775 | $3,144 | 54.4% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 19 | 35 | $2,418 | $1,470 | 60.8% |
| 0031A | Adm sarscov2 vac ad26 .5ml | Office | 2021 | 22 | 22 | $1,518 | $924.22 | 60.9% |
| 0001A | Adm sarscov2 30mcg/0.3ml 1st | Office | 2021 | 11 | 11 | $789.00 | $462.11 | 58.6% |
| 99421 | Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | Facility | 2020 | 15 | 15 | $1,066 | $184.35 | 17.3% |
About Jennifer Burns
Jennifer Burns is a Pediatrics, Critical Care healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1487776399.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jennifer Burns has received a total of $1,372 in payments from pharmaceutical and medical device companies, with $1,347 received in 2024. These payments were reported across 13 transactions from 3 companies. The most common payment nature is "" ($1,347).
As a Medicare-enrolled provider, Burns has provided services to 402 Medicare beneficiaries, totaling 418 services with total Medicare billing of $30,191. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Practice Information
- Specialty Pediatrics, Critical Care
- Other Specialties Critical Care
- Location Chicago, IL
- Active Since 04/04/2007
- Last Updated 10/24/2022
- Taxonomy Code 363LP0222X
- Entity Type Individual
- NPI Number 1487776399
Products in Payments
- PREVNAR 13 (Biological) $12.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics, Critical Care Doctors in Chicago
Miranda Foote
Pediatrics, Critical Care — Payments: $350.85
Ms. Janis Quinn, Rn, Msn, Cpnp-Ac, RN, MSN, CPNP-AC
Pediatrics, Critical Care — Payments: $177.90
Emily Whitlow, Aprn, APRN
Pediatrics, Critical Care — Payments: $156.44
Jacqueline Elegant, Np, NP
Pediatrics, Critical Care — Payments: $148.90
Dr. Emma Gersch, Pnp-Ac, PNP-AC
Pediatrics, Critical Care — Payments: $107.17
Mrs. Beth Bolick, Rn Cnp, RN CNP
Pediatrics, Critical Care — Payments: $77.05